Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 19, 2018
Reporting Period: Event date of July 19, 2018
The Company, a Nevada corporation, reported a strategic business development involving its subsidiary, Caverstem International LLC.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
Commercialization Agreement: On July 19, 2018, the Company's subsidiary, Caverstem International LLC, signed an exclusive contract with Promo Med Russia. This agreement covers the commercialization of the Company's CaverStem technology.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The press release associated with this filing (Exhibit 99.1) contains forward-looking statements based on information available as of the date made.
- Risk Factors: Actual results may differ materially from anticipated results due to various factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent SEC filings.
- Management Commentary: Management advises that undue reliance should not be placed on forward-looking statements. The Company assumes no duty to update these statements unless required by applicable securities law.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific terms of the exclusive contract with Promo Med Russia.
- Examine the Company's Form 10-K for the year ended December 31, 2017, to understand the risk factors associated with the CaverStem technology and international commercialization.
- Verify the regulatory status and commercial readiness of the CaverStem technology in the Russian market.
- Check subsequent filings for any updates or revisions to the forward-looking statements made in this report.